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Abstract: The role of endogenous fibrinolysis
in cerebral infarction has been investigated,
but with conflicting results. In this study,
variations of tissue-type plasminogen
activator (t-PA) antigen concentrations over
time after stroke were examined at the acute
and subacute phases of ischemic stroke in a
group of patients and in a control group. The
relationships between t-PA levels and stroke
severity, lesion volume and clinical status were
also investigated.
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This study was carried out in 45 patients with
acute ischemic stroke and 21 control subjects
who had similar characteristics. Levels of t-PA
mass concentration were measured via the
ELISA, while Student’s t, Chi-square and
Pearson correlation methods were used.

Introduction
The majority of acute ischemic strokes in humans are
due to thrombotic or thromboembolic occlusions (1,2).
Several individual risk factors for ischemic stroke such as
hypertension, smoking, hypercholesterolemia and obesity
are also well known (1-4).
T-PA, 70,000 D mass, containing 517 amino acids
composed of single serine protease, is synthesized by
endothelial cells and levels which are related to the
fibrinolytic system. Increased levels reflect increased
fibrinolytic activity. It is a poor enzyme in the absence of
fibrin, but in the presence of fibrin it strikingly enhances
the activation rates of plasminogenesis. Its concentration
is high in small vessels and renal vasculature. In normal
conditions t-PA is low in plasma (5-10 ng/ml) and shows
circadian rhythm (5). T-PA has been reported as an
independent predictor for an atherothrombotic event,
mostly in patients with cardiovascular disease. In
addition, plasma levels of t-PA have emerged as a strong
predictor of myocardial infarction (6-9). The
neuroprotective effects of t-PA were demonstrated in

Age ratio (57.42 ± 15.36, 53.19 ± 10.45, P
= 0.2) and sex distribution (F/M: 24/21,
9/12, P = 0.42) of the patients and the
control group were the same. The average tPA values of the patients were considerably
higher than those of the control group during
acute and subacute periods [(17.9 ± 8.1
ng/ml, 26.3 ± 17.9 ng/ml) vs. (9.9 ± 3.8
ng/ml), (P < 0.001)]. No significant relation
was found between t-PA either with infarct
size nor with clinical neurologic status.
These results suggest that increased t-PA
levels exist in ischemic stroke and the
endogenous fibrinolytic system is activated
during acute and subacute periods of ischemic
stroke.
Key Words: ischemic stroke, risk factors,
tissue plasminogen activator, t-PA

initial experimental stroke studies in animal models
(10,11). Some studies strongly suggest that t-PA
protects the brain from ischemic insult through its
desirable thrombolytic action (12,13). The cerebral
protective effects of t-PA were also shown in earlier
stroke studies, which led to clinical trials with t-PA
(14,15). The role of t-PA in cerebrovascular diseases
have received less attention, and only a few studies have
considered aspects of hemostasis in ischemic stroke
patients (16-20). High levels of t-PA have been observed
in patients with a history of stroke, while in prospective
studies high levels of t-PA predicted an increased risk of
stroke (14,21,22). In this study, we aimed to evaluate tPA mass concentration and its possible relationship with
other vascular risk factors in a group of patients with a
first ischemic stroke.

Materials and methods
This study was based on 45 consecutive patients, aged
20 to 80 years, admitted to our neurology department as
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a result of their first ever stroke. The control group
comprised 21 subjects without stroke, randomly selected
from the outpatient clinic. The study design was approved
by our local university ethical committee and informed
consent was obtained from all subjects or their relatives
if the patient was unable to communicate.
The diagnostic investigation included CT or MR of the
brain, duplex ultrasonography of the cervical arteries,
echocardiography and detailed laboratory studies. The
infarct size was calculated based on the maximum length
and width of the hypodense area on the CT films. To
calculate irregular volumes we used the following
formula: A x B x C / 2 (23). We measured the largest
diameter (A) and the perpendicular diameter (B) of the
ischemic lesion and the third diameter (C) by summing up
the thicknesses of the slices where the lesion was visible.
Clinical neurologic status was evaluated according to a
modified Matthew Scale (MMS). The patients were
subclassified into a mild neurologic deficit group (MMS ≥
50) a and severe neurologic deficit group (MMS score <
50).
Blood samples were taken from all patients within 3 d
of acute stroke onset. Only 28 out of the 45 patients
were re-examined during the subacute (2-3 weeks)
period because 10 patients died and we lost contact with
five. Antecubital venipuncture with a 21-gauge butterfly
needle was performed by the same physician between
07.30 and 09.00 hours to minimize circadian variability
in fibrinolytic measures. Venipuncture was performed on
a reclining subject without tourniquet to avoid
augmenting of t-PA release, which is known to
accompany venous stasis, physical exertion and
orthostatic changes. (24). Blood was drawn after a
minimum of 10 min rest in the recumbent position. The
first 5 ml of blood was discarded and next 9 ml was
collected directly into precooled tubes that contained
sodium citrate. The tubes were gently inverted, then
immediately centrifugated at 2000 g for 30 min. The
recovered plasma was frozen at –80 °C until analysis.
The mass concentration of t-PA in plasma (in previous
studies often termed t-PA antigen) was determined with
an enzyme-linked immunosorbent assay (Biopool
TintElizet-PA) that detects t-PA in complex. For t-PA
mass concentration, the coefficient of variation at 8 µg/l
was 9.5% according to the manufacturer (25).
Comparisons between patients and controls were
made with Student’s t test or the Mann-Whitney U test

156

for continuous variables. The Chi-square or Fisher’s exact
test were used for proportions. Spearman correlation
coefficients (rs) were applied to test for correlations
between continuous variables.

Results
We found no statistically significant differences
between patients and control subjects regarding age, sex
distribution, body mass index, diabetes mellitus and
current smoking or alcohol intake. The rate of
hypertension and hypercholesterolemia were higher in
the patient group than in the control group. For both
patients and control subjects, the basic clinical features,
demographic characteristics, and t-PA levels according to
stage, clinical neurological status and prognosis are
shown in the Table and Figure. There was no significant
difference between males and females regarding t-PA
mass concentration.
In patients with ischemic stroke, t-PA mass
concentration levels were significantly increased in all
periods compared with those of the controls (P < 0.001),
and showed no substantial changes between periods,
although t-PA mass concentration was slightly higher in
the subacute period than in the acute period.
Table.

The basic clinical features, demographic characteristics,
and t-PA levels of the control subjects and patients
according to stage, clinical neurological status and
prognosis.
Patients
N = 45

Controls
N = 21

P

Age
Sex

57.42 ± 15.36

53.19 ± 10.45

0.2

Male/Female
2
Body mass index, kg/m
Current Smokers
Alcohol
Obesity
Hypercholesterolemia
Diabetes mellitus
Hypertension
T-PA mass concentrations
Acute stage n = 45
Subacute stage n = 31
MMS score ≥ 50 n = 24
MMS score < 50 n = 21
Surviving patients 30
Deceased patients 10

24/21

9/12

0.42

19 (42.2%)
4 (8.9%)
25 (56.6%)
21 (46.7%)
12(26.7%)
31(68.9%)

7
2
8
5
3
7

(33.3%)
(9.5%)
(38.1%)
(23.8%)
(14.3%)
(33.3%)

0.59
0.93
0.29
0.07
0.26
0.006

17.9
18.7
18.5
17.2
19.8
16.9

9.38 ± 3.4

0.001

±
±
±
±
±
±

8.1
17.9
8.4
7.9
9.7
7.1

Values are numbers of subjects or mean ± SD, as appropriate
T test or Mann-Whitney U test for continuous variables; Chi-square or Fisher’s
exact test for proportions.
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subacute phase

controls

Bar graph shows the distributions of plasma t-PA mass
concentrations in patients and controls.

No significant relations were found at the P < 0.05
significance level between t-PA levels and stroke risk
factors including body mass index, smoking, cholesterol
levels or blood pressure.
Regarding infarct size, which ranged from 0.30 ml to
600.00 ml (112.2 ± 192.3), no correlation was found
with t-PA mass concentration at the acute and subacute
phase of stroke (acute P = 0.68, r = 0.064; subacute r =
0.09, P = 0.65).
Patients who died did not differ from those who
survived regarding t-PA mass concentration in the acute
phase (Table). Regarding t-PA mass concentration levels,
no significant difference was determined between stroke
patients having MMS > 50 from those with MMS < 50,
and between patients who died and survived.

Discussion
We found that t-PA concentrations in the acute and
subacute period of acute ischemic were significantly
increased compared with controls, in agreement with the
findings of most previous studies (9,21,26), though not
all (14). Although the t-PA mass concentration of our
patients before stroke is unknown, the sustained
elevation of t-PA levels in the subacute period may
indicate increased baseline t-PA levels in patients with
ischemic stroke. Although the clinical importance of
increased fibrinolytic activity in acute stroke is unclear,
previous reports show that fibrin formation may greatly
exceed endogenous fibrinolysis during acute ischemic
stroke and may indicate that the acute stroke phase is an
acute hypercoagulable state (9,21). Altered fibrinolytic
activity is considered as an acute phase reaction in many
studies. It can be thought that a high level of t-PA is a

vascular risk factor already present before the stroke (9).
The reported finding that fibrin formation may greatly
exceed endogenous fibrinolysis during the acute phase of
ischemic stroke may indicate that the acute stroke phase
is an acute hypercoagulable state (12,13,27). T-PA has
been suggested to be an acute phase reactant. In patients
with angina pectoris, t-PA antigen levels have been found
to correlate with levels of acute phase protein fibrinogen,
C reactive protein (28).
However, it is possible that the acute-phase increases
of t-PA are very short. Thus, in previous studies, t-PA
levels increased immediately after surgery but returned
to baseline values within 24 h (29,30).
Because stroke is also an acute event followed by a
convalescent phase, the findings of these surgical studies
may have an implication for the interpretation of our
findings.
In our study, the early rapid increases in the t-PA
antigen were probably undetected because most of the
blood samples were collected 1 to 3 d after the onset of
stroke. Although t-PA antigen levels may increase as an
acute-phase reaction, this increase is often of very short
duration, and our follow-up results show that increases in
t-PA antigen levels among stroke patients cannot be
explained solely by an acute-phase reaction. Thus, it is
conceivable that impaired fibrinolysis preexisted in our
stroke patients and less likely that it represents a
phenomenon secondary to the stroke event. Accumulated
evidence suggests that elevated t-PA antigen levels may
indicate an increased risk of stroke.
The results from the previous prospective studies in
which a high plasma t-PA mass concentration was found
to be predictive of stroke (9,18,25,26) and myocardial
infarction (6-8,33,34) are in accordance with our finding
that stroke patients have a higher acquired t-PA mass
concentration level (19).
Our findings are also in accordance with those of
earlier studies and show that high t-PA antigen levels can
be found in the same group of individuals examined in
either the acute or subacute phase after stroke
(19,21,26,35). Our results show that infarct size is not
related to t-PA concentration in the acute and subacute
stage of stroke. There were no correlations between
MMS and plasma t-PA levels. These findings show that tPA levels are not an indicator for prognosis in ischemic
cerebrovascular disease.
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